Serum paraoxonase/arylesterase 1 (PON1) Antibody (FITC)

Product Graph
260€ (50 µl)

Por favor contáctenos para obtener información detallada sobre el precio y disponibilidad.

935106861
info@markelab.com
name
Serum paraoxonase/arylesterase 1 (PON1) Antibody (FITC)
category
Primary Antibodies
provider
Abbexa
reference
abx344160

Description

Serum paraoxonase/arylesterase 1 (PON1) Antibody (FITC) is a Rabbit Polyclonal antibody conjugated to FITC for the detection of Human PON1.

Documents del producto

Instrucciones
Data sheet
Descargar

Product specifications

Category
Primary Antibodies
Immunogen Target
Target: Serum paraoxonase/arylesterase 1 (PON1)
Immunogen: Recombinant Human Serum paraoxonase/arylesterase 1 protein (103-355 AA)
Host
Rabbit
Reactivity
Human
Detection Method
Laser Line: 488
Excitation/Emission: 499/515
Recommended Dilution
Optimal dilutions/concentrations should be determined by the end user.
Clonality
Polyclonal
Conjugation
FITC
Isotype
IgG
Purity
> 95%
Purification
Purified by Protein G chromatography.
Size 1
50 µl
Size 2
100 µl
Size 3
200 µl
Size 4
1 ml
Form
Liquid
Buffer
0.01 M PBS, pH 7.4, 0.03% Proclin-300 and 50% glycerol.
Availability
Shipped within 5-10 working days.
Storage
Aliquot and store at -20°C. Avoid repeated freeze/thaw cycles.
Dry Ice
No
UniProt ID
P27169
Gene ID
5444
OMIM
168820
Background
Antibody anti-PON1
Status
RUO
Note
THIS PRODUCT IS FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC, THERAPEUTIC OR COSMETIC PROCEDURES. NOT FOR HUMAN OR ANIMAL CONSUMPTION.

Descripción

Related Products

EH0257

Human PON1 (Serum paraoxonase/arylesterase 1) ELISA Kit

Ver Producto
ER0265

Rat Pon1 (Serum paraoxonase/arylesterase 1) ELISA Kit

Ver Producto
FNab06638

PON1 antibody

Hydrolyzes the toxic metabolites of a variety of organophosphorus insecticides. Capable of hydrolyzing a broad spectrum of organophosphate substrates and lactones, and a number of aromatic carboxylic acid esters. Mediates an enzymatic protection of low density lipoproteins against oxidative modification and the consequent series of events leading to atheroma formation.

Ver Producto